Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

Authors :: Rebecca Olsen
Jonathan I. Silverberg
Rebecca Zachariae
Eric L. Simpson
Andreas Wollenberg
Joseph F. Merola
Source :: SKIN The Journal of Cutaneous Medicine. 5:s11
Publication Year :: 2021
Publisher :: National Society for Cutaneous Medicine, 2021.
Abstract: not available.

Subjects :: Moderate to severe
medicine.medical_specialty
Adult patients
business.industry
Atopic dermatitis
medicine.disease
Placebo
Gastroenterology
Double blind
Pooled analysis
Internal medicine
Interleukin 13
medicine
business
Tralokinumab

Full Text Access

Tools